Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of SPY001-001, SPY002, and SPY003 alone or in combination in ulcerative colitis
2025-524640-35-00Phase 2Authorised
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 37
01
Overview
Phase 2, open-label, single-arm trial of SPY001, SPY002 and SPY003 in autoimmune colitis, sponsored by Spyre Therapeutics, Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Aug 2026; status: authorised.
02
Drugs
SPY001SPY002SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-524640-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524640-35-00.